Article Details

Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in ... - PR Newswire

Retrieved on: 2022-05-21 11:08:52

Tags for this article:

Click the tags to see associated articles and topics

Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in ... - PR Newswire. View article details on hiswai:

Excerpt

... monoclonal antibody that binds to and blocks the function of ANGPTL3, ... FDA-approved fully human monoclonal antibodies currently available.

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up